REMARKS:

The preceding claim amendments and the following remarks are submitted as a full and complete response to the Office Action issued on February 24, 2009. Claim 4 has been amended to insert the unit "daltons" for "a molecular weight cut-off of 10,000" and to reflect the suggestion by the Patent Office to improve the syntax of claim 4. No new matter has been added. Accordingly, claims 1-5 are pending.

Objection and Rejection under 35 U.S.C. §112

The Patent Office has suggested amending claim 4 to recite the phrase "with an ultrafiltration membrane with a molecular [weight] cut-off of 10,000," and to specify the appropriate molecular weight units. The Patent Office has also rejected claim 4 under 35 U.S.C. §112 as indefinite for not reciting any units for a molecular weight cut-off of 10,000. Applicants respectfully submit that since it is common knowledge that the unit of a molecular weight cut-off in ultrafiltration is daltons, one skilled in the art would have readily understood the invention of claim 4 without a need of specifying the unit for "a molecular weight cut-off of 10,000." Nonetheless, considering the Patent Office's suggestion, Applicants have revised claim 4 to recite the phrase "with an ultrafiltration membrane with a molecular weight cut-off of 10,000 daltons," for purposes of additional clarification only. Accordingly, reconsideration and withdrawal of the objection and rejection of claim 4 are respectfully requested.

¹ It appears that the Patent Office inadvertently omits the word "weight" in its proposed language.

Claim Rejections under 35 U.S.C. §103(a)

The Patent Office has rejected claims 1-5 under 35 U.S.C. §103(a) as obvious over Utsumi, et al. (Eur. J. Biochem, 1989, Vol. 181, pp. 545-553) ("Utsumi"), in view of Carter et al. (U.S. Patent No. 4,483,849) ("Carter"), and further in view of Revel et al. (U.S. Patent No. 4,808,523) ("Revel"). While acknowledging that Utsumi does not teach the use of propylene glycol-containing buffers, the Patent Office alleges that one skilled in the art would have been motivated to use buffers containing propylene glycol for purification of IFN-β by affinity chromatography in view of the teachings of Carter or Revel, either alone or in combination. The Patent Office further alleges that although neither Carter nor Revel discloses "all of the exact claimed propylene glycol concentration ranges," one skilled in the art would have both the motivation and the ability to optimize the concentration of propylene glycol in the buffers of either Carter or Revel. Applicants respectfully disagree.

As recited in claim 1, the claimed method for purifying human IFN-β comprises washing the column with both a washing buffer solution A and a washing buffer solution B. The two washing buffer solutions A and B are different not only in their concentrations of polyethylene glycol but also in the presence of NaCl as an ingredient. That is, while the washing buffer solution A of pH 6.5-7.5 contains 30-60 wt% of propylene glycol as an essential ingredient, the washing buffer solution B of pH 6.5-7.5 contains 10-30 wt% of propylene glycol and 1-2M of NaCl as ingredients. In addition to these two washing buffer solutions, a buffer solution of pH 6.5-7.5 containing 40-60 wt% of propylene glycol and 1-2M NaCl is used to elute a human IFN-β in claim 1.

Utsumi discloses a process of purifying HuIFN-β comprising applying culture fluid

containing each mammalian-cell derived recombinant HulFN-β1 to a column of blue Sepharose CL-6B, washing with 20 mM phosphate pH 7.4 containing 2 M NaCl and 30% ethylene glycol and eluting with 20 mM phosphate pH 7.4 containing 1M NaCl and 60% ethylene glycol. While Utsumi discloses a washing buffer solution containing 2M NaCl and 30% ethylene glycol, Utsumi fails to disclose using two different washing buffer solutions such as washing buffer solutions A and B as recited in claim 1, let alone using a washing buffer solution containing propylene glycol for purifying HulFN-β.

Although Carter discloses using 40% of propylene glycol as a washing buffer solution for a column loaded with IFN-β, it fails to teach or suggest using additional washing buffer solution containing propylene glycol together with the washing buffer solution disclosed in Carter. Thus, Carter also fails to teach or suggest using two different washing buffer solutions.

Revel does not cure this deficiency in the teaching of Carter or Utsumi because the teaching of Revel is limited to use a buffer solution containing 40% of propylene glycol and 1M NaCl for eluting IFN. Revel does not even mention using a buffer solution for washing the column prior to elution of IFN, let alone using two different washing buffer solutions. That is, neither Carter nor Revel teaches or suggests using two washing buffer solutions: a washing buffer solution containing 30-60 wt% of propylene glycol and a washing buffer solution containing 10-30% of propylene glycol and 1-2M NaCl.

Contrary to the Patent Office's position, none of the cited references provides a motivation for one skilled in the art to use two different washing buffer solutions. As the Patent Office admits, Utsumi is silent in using propylene glycol either as a washing

buffer solution or as an eluting buffer solution. Although Carter discloses using 40% propylene glycol in 1.0 M NaCl/PO₄ buffer as a washing buffer solution, this disclosure is limited to just a single working example. In contrast, as evident from various disclosures in Carter, the thrust of the teachings and the suggestions of Carter is using a solution of propylene glycol as an eluting solution for IFN-β instead of ethylene glycol See e.g., claim 1; col. 1, lines 35-54; col. 2, lines 29-40; col. 3, lines 54-68; and Example 2. Indeed, Carter consistently teaches 1:1 mixture of 2M NaCl buffered at neutral pH with sodium phosphate and propylene glycol, which is referred to as 50% propylene glycol. for eluting IFN-ß from a solid matrix. That is, while Carter teaches using the 50% propylene glycol instead of 60% of ethylene glycol for eluting IFN-8 to obtain a higher purification yield, it is completely silent as to how to modify a washing buffer solution in purification of IFN-B except for using a single washing solution containing 40% propylene glycol in 1.0M NaCl. Therefore, Carter fails to provide any motivation for one skilled in the art to modify using propylene glycol as a washing buffer solution such as using two different propylene glycol solutions. Applicants respectfully submit that this lack of disclosure regarding using two different propylene glycol solutions as washing buffer solutions cannot be cured under the theory of routine optimization because the missing disclosure is plainly a claim element.

To establish *prima facie* obviousness of a claimed invention, all the claim elements must be taught or suggested by the prior art. <u>See In re Royka</u>, 180 USPQ 580 (CCPA 1974). Since Utsumi, Carter and Revel, alone or in combination, fail to teach or suggest all the elements of claim 1, there is no *prima facie* case of obviousness established, which warrants withdrawal of this obviousness rejection. The remaining

U.S. Serial Number 10/581,602 Response to Office Action dated 2/24/2009 Page 8

claims 2-5 are dependent on claim 1. Thus, claims 2-5 would not have been obvious over Utsumi in view of Carter, and further in view of Revel for the same reason for claim 1.

Accordingly, Applicants respectfully request reconsideration and withdrawal of all the obviousness rejections.

Double Patenting

The Patent Office has provisionally rejected claims 1-5 as unpatentable over claims 1-5 of copending Application No. 10/581,597 under the obviousness-type double patenting. In view of the provisional nature of this rejection, Applicants will address this rejection once allegedly conflicting claims are in fact patented.

In light of the foregoing, Applicants submit that all outstanding rejections have been overcome, and the instant application is in condition for allowance. Thus, Applicants respectfully request early allowance of the instant application. The Commissioner is hereby authorized to charge any fees or credit any overpayment to Deposit Account No. 02-2135.

Respectfully submitted.

Bv:

doseph A. Hynds Registration No. 34,627

Attorrey for Applicants
ROTHWELL, FIGG, ERNST & MANBECK

1425 K. Street, Suite 800 Washington, D.C. 20005 Telephone: (202) 783-6040

1610231_1